Literature DB >> 17851561

The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders.

C Bellanné-Chantelot, P Jego, P Lionne-Huyghe, M Tulliez, A Najman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17851561     DOI： 10.1038/sj.leu.2404896

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.

Authors:  Joseph Saliba; Cécile Saint-Martin; Antonio Di Stefano; Gaëlle Lenglet; Caroline Marty; Boris Keren; Florence Pasquier; Véronique Della Valle; Lise Secardin; Gwendoline Leroy; Emna Mahfoudhi; Sarah Grosjean; Nathalie Droin; M'boyba Diop; Philippe Dessen; Sabine Charrier; Alberta Palazzo; Jane Merlevede; Jean-Côme Meniane; Christine Delaunay-Darivon; Pascal Fuseau; Françoise Isnard; Nicole Casadevall; Eric Solary; Najet Debili; Olivier A Bernard; Hana Raslova; Albert Najman; William Vainchenker; Christine Bellanné-Chantelot; Isabelle Plo
Journal:  Nat Genet       Date:  2015-08-17       Impact factor: 38.330

2.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

3.  Low burden of a JAK2-V617F mutated clone in monoclonal haematopoiesis in a Japanese woman with Budd-Chiari syndrome.

Authors:  Kohtaro Toyama; Masamitsu Karasawa; Arito Yamane; Hiromi Koiso; Akihiko Yokohama; Hideki Uchiumi; Takayuki Saitoh; Hiroshi Handa; Ken Sato; Hitoshi Takagi; Shuichi Miyawaki; Hirokazu Murakami; Yoshihisa Nojima; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2009-03-24       Impact factor: 2.490

Review 4.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors:  A Tefferi
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.